XOMA CORP 8.625% CUM PERP PFD SER A News

XOMA Royalty Significantly Expands Its Royalty and Milestone Portfolio With the Addition of Over 60 Early-Stage Programs From Twist Bioscience

GlobeNewswireOct 22 08:00 ET

XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On October 3rd, 2024 With 0.53906 USD Dividend Per Share

Moomoo NewsSep 23 19:40 ET

Zevra's MIPLYFFA (Arimoclomol) Receives Approval From U.S. Food and Drug Administration for Use in Patients With Niemann-Pick Disease Type C (NPC)

GlobeNewswireSep 23 06:30 ET

XOMA Royalty to Present at Upcoming Investor Conferences in September

GlobeNewswireSep 4 07:30 ET

10-Q: Q2 2024 Earnings Report

SECAug 13 07:42 ET · Announcements

XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On July 3rd, 2024 With 0.53906 USD Dividend Per Share

Moomoo NewsJun 20 19:40 ET

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of Its Priority Review Voucher

GlobeNewswireJun 12 07:30 ET

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

GlobeNewswireMay 14 07:30 ET

10-Q: Q1 2024 Earnings Report

SECMay 9 07:37 ET · Announcements

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Stockhouse May 9 07:30 ET

XOMA Adds Economic Interests in Three First-in-Category Assets to Its Royalty and Milestone Portfolio Including XACIATO (Clindamycin Phosphate) Vaginal Gel 2%

GlobeNewswireApr 30 07:30 ET

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (Tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (PLGG)

GlobeNewswireApr 25 07:30 ET

XOMA Corporation Announces Closing of Tender Offer

Globe NewswireApr 3 09:00 ET

XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On April 2nd, 2024 With 0.53906 USD Dividend Per Share

Moomoo NewsMar 21 20:45 ET

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

GlobeNewswireMar 19 16:05 ET

XOMA to Present at Upcoming Investor Conferences in March

GlobeNewswireFeb 28 07:30 ET

XOMA Enters Into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

GlobeNewswireFeb 16 08:00 ET

Express News | Trading Halt: Halted at 7:55:00 A.m. ET - Trading Halt: Halt News Pending

Moomoo 24/7Feb 16 07:55 ET

XOMA Expands Its Commercial Royalty and Milestone Portfolio With DSUVIA Acquisition

GlobeNewswireJan 18 08:30 ET

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

GlobeNewswireJan 11 16:05 ET